Sabinsa Corp. now holds a U.S. patent for the company’s shelf-stable Bacillus coagulans MTCC 5856 probiotic ingredient, brand name LactoSpore, for therapeutic management of irritable bowel syndrome (IBS).
Photo © iStockphoto.com/Artem_Furman
Sabinsa Corp. (East Windsor, NJ) now holds a U.S. patent for the company’s shelf-stable Bacillus coagulans MTCC 5856 probiotic ingredient, brand name LactoSpore, for therapeutic management of irritable bowel syndrome (IBS).
The patent (No. US9579352) relates to LactoSpore’s ability, concurrently with regular treatment, to help manage IBS symptoms such as abdominal pain, bloating or visible distension of the abdomen, constipation, and loose stools when the ingredient is administered orally as a dietary supplement in a dosage not less than 2 billion spores.
This ability was most recently backed by a published human study last year in Nutrition Journal that found that subjects taking 2 x 109 CFU/day of B. coagulans MTCC 5856 for 90 days saw decreases over the placebo group in symptoms such as bloating, vomiting, diarrhea, abdominal pain, and stool frequency.
In Canada, LactoSpore can be sold under the health claim, “Helps relieve abdominal pain associated with IBS.”
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
U.S. Hemp Authority announces Adult Use Hemp Product Certification Program
April 15th 2024The U.S. Hemp Authority (USHA) has announced the launch of its Adult Use Hemp Product Certification Program in an effort to “reshape public policy around hemp, and to build confidence among retailers and consumers alike.”